Michael Metzger is Chief Executive Officer of Syndax Pharmaceuticals Inc (SNDX). The company reported total compensation of $7,089,213 for fiscal year 2025.
| Salary | $754,300 |
|---|---|
| Bonus | $0 |
| Stock awards | $2,021,965 |
| Option awards | $3,454,360 |
| Non-equity incentive plan | $848,588 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $10,000 |
| Total | $7,089,213 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Syndax Pharmaceuticals Inc filed April 30, 2026, accession 0001193125-26-197859.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $754,300 | $0 | $2,021,965 | $3,454,360 | $848,588 | $0 | $10,000 | $7,089,213 |
| FY2024 | President and Chief Executive Officer | $715,000 | — | $3,258,450 | $3,208,211 | $515,515 | — | $10,000 | $7,707,176 |
| FY2023 | President and Chief Executive Officer | $678,400 | — | — | $8,023,803 | $417,216 | — | $8,000 | $9,127,419 |
Totals as disclosed in each year's own compensation disclosure for Syndax Pharmaceuticals Inc.
| Peer-group chief executive median | $10,331,490 |
|---|---|
| Difference from that median | $-3,242,276 |
| Percentile within the disclosed peer group | 32nd |
| Peers with a disclosed figure | 21 |
Medians and percentiles are computed across the peer group Syndax Pharmaceuticals Inc discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael Metzger this page | Chief Executive Officer | $7,089,213 |
| Nick Botwood | Head of Research and Development, Chief Medical Officer | $2,879,099 |
| Keith Goldan | Chief Financial Officer | $2,470,802 |
| Luke Albrecht | General Counsel and Secretary | $2,331,617 |
| Steve Closter | Chief Commercial Officer | $2,125,887 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Syndax Pharmaceuticals Inc compensation brief.
Michael Metzger's compensation sits inside Syndax Pharmaceuticals Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.